CROSSJECT (EPA:ALCJ)

PRESS RELEASE

published on 05/20/2025 at 07:30, 1 year 2 months ago

CROSSJECT prepares for the launch of a capital increase with preferential subscription rights of around 5 million euros in preparation for commercial and production activities linked to EUA approval
CROSSJECT plans 5 million euros capital increase, may increase to 5.8 million euros, Gemmes Venture to guarantee 75% of initial amount, Heights Capital Management supports offer

Capital Increase Crossject Gemmes Venture Heights Capital Management EUA Approval
BRIEF

published on 05/07/2025 at 07:35, 1 year 2 months ago

CROSSJECT: Progress in the EUA authorization application for ZEPIZURE®

FDA USA ZEPIZURE® BARDA CHEMPACK
BRIEF

published on 03/27/2025 at 07:35, 1 year 3 months ago

CROSSJECT Publishes 2024 Financial Results

Financial Results Cash Position Partnerships FDA Filing ZEPIZURE®
PRESS RELEASE

published on 03/27/2025 at 07:30, 1 year 3 months ago

CROSSJECT reports financial results for 2024
CROSSJECT reports financial results for 2024 and progress in clinical and regulatory activities, recruitment of COO, and increased cash position. Key achievements and future plans outlined

Financial Results Cash Position Clinical Activities Crossject Regulatory Development
BRIEF

published on 03/25/2025 at 07:35, 1 year 3 months ago

Strategic partnership between CROSSJECT and ETON PHARMACEUTICALS

Eton Pharmaceuticals Crossject ZENEO® Hydrocortisone Adrenal Insufficiency
PRESS RELEASE

published on 03/25/2025 at 07:30, 1 year 3 months ago

CROSSJECT updates on its collaboration with ETON PHARMACEUTICALS, Inc. and the ZENEO® adrenal insufficiency program
CROSSJECT enhances collaboration with ETON PHARMACEUTICALS Inc. on ZENEO adrenal insufficiency program, introducing new hydrocortisone formulation for the hospital market

Eton Pharmaceuticals Crossject Hydrocortisone Adrenal Insufficiency ZENEO
BRIEF

published on 03/10/2025 at 14:22, 1 year 4 months ago

Crossject: Update on voting rights and shares as of January 31, 2025

Share Capital Voting Rights Actions Pharmaceutical Crossject
BRIEF

published on 02/12/2025 at 07:35, 1 year 5 months ago

Crossject Reappoints Key Members to Executive Board

Executive Board Crossject ZEPIZURE® Reappointment Needle-free Technology
PRESS RELEASE

published on 02/12/2025 at 07:30, 1 year 5 months ago

Crossject announces the reappointment of Patrick Alexandre and Isabelle Liebschutz as members of new, streamlined Executive Board
Crossject reappoints Patrick Alexandre and Isabelle Liebschutz to its Executive Board, focusing on final stages of ZEPIZURE registration with the FDA

Executive Board Crossject Patrick Alexandre Isabelle Liebschutz ZEPIZURE Registration
BRIEF

published on 02/06/2025 at 07:35, 1 year 5 months ago

Modification of Convertible Bonds by Crossject

Convertible Bonds Funding Crossject ZEPIZURE Heights Capital

Published on 07/21/2026 at 22:30, 19 minutes ago

Fermi Announces First Siemens Turbines Arrive at Port of Houston
Published on 07/21/2026 at 22:30, 19 minutes ago

Matador Technologies Announces Management Transition
Published on 07/21/2026 at 22:15, 34 minutes ago

Vanta Announces Updated Time for Participation in the "Health, Wellness & Longevity" Virtual Conference Presented by Maxim Group LLC on Wednesday, July 22, 2026, at 12:00 p.m. ET
Published on 07/21/2026 at 22:00, 49 minutes ago

Redwood AI Announces Closing of $3.5 Million Private Placement
Published on 07/21/2026 at 17:05, 5 hours 44 minutes ago

Caldwell Appoints Steven Price Co-Leader of Life Sciences & Healthcare Practice

View all ACCESSWIRE

Published on 07/21/2026 at 22:30, 18 minutes ago

Strong second quarter: GEA raises full-year guidance for 2026
Published on 07/21/2026 at 22:16, 32 minutes ago

EQS-Adhoc: GEA Group Aktiengesellschaft: Preliminary numbers for Q2 2026 exceed market expectation - increase of guidance for fiscal year 2026
Published on 07/21/2026 at 18:50, 3 hours 58 minutes ago

Soapeya, a DN Group AG Portfolio Company, Earns Top "Excellent" Rating from Dermatest and Proves Successful in Field Use in Ghana
Published on 07/21/2026 at 18:15, 4 hours 33 minutes ago

EuroTeleSites Reports Strong Q2/2026 Results with Growth Across Key Financial and Operating Metrics
Published on 07/21/2026 at 17:50, 4 hours 58 minutes ago

The New Measure of an EV Isn't Range, It's Peace of Mind

View all EQS

Published on 07/21/2026 at 18:41, 4 hours 7 minutes ago

ICADE - 2026 HY Financial Report
Published on 07/21/2026 at 18:13, 4 hours 35 minutes ago

ICADE – PR – 2026 HALF YEAR RESULTS
Published on 07/20/2026 at 18:20, 1 day 4 hours ago

Covivio - 2026 Half-year results: Earnings growth driven by active asset management
Published on 07/20/2026 at 18:04, 1 day 4 hours ago

Reporting on share buyback transactions carried out between July 8 and July 9, 2026
Published on 07/20/2026 at 17:45, 1 day 5 hours ago

Weekly share buyback

View all LES ECHOS COMFI WIRE

News